



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO.                                                             | FILING DATE | FIRST NAMED INVENTOR  | ATTORNEY DOCKET NO. | CONFIRMATION NO.     |
|-----------------------------------------------------------------------------|-------------|-----------------------|---------------------|----------------------|
| 10/596,202                                                                  | 06/02/2006  | Johannes Bartholomaus | 512100-2056         | 3372                 |
| 20999                                                                       | 7590        | 01/31/2011            | EXAMINER            |                      |
| FROMMER LAWRENCE & HAUG<br>745 FIFTH AVENUE- 10TH FL.<br>NEW YORK, NY 10151 |             |                       |                     | SULLIVAN, DANIELLE D |
| ART UNIT                                                                    |             | PAPER NUMBER          |                     |                      |
| 1617                                                                        |             |                       |                     |                      |
| MAIL DATE                                                                   |             | DELIVERY MODE         |                     |                      |
| 01/31/2011                                                                  |             | PAPER                 |                     |                      |

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

|                                                                 |                        |                     |  |
|-----------------------------------------------------------------|------------------------|---------------------|--|
| <b>Advisory Action<br/>Before the Filing of an Appeal Brief</b> | <b>Application No.</b> | <b>Applicant(s)</b> |  |
|                                                                 | 10/596,202             | BARTHOLOMAUS ET AL. |  |
|                                                                 | <b>Examiner</b>        | <b>Art Unit</b>     |  |
|                                                                 | DANIELLE SULLIVAN      | 1617                |  |

**--The MAILING DATE of this communication appears on the cover sheet with the correspondence address --**

THE REPLY FILED 14 January 2011 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE.

1.  The reply was filed after a final rejection, but prior to or on the same day as filing a Notice of Appeal. To avoid abandonment of this application, applicant must timely file one of the following replies: (1) an amendment, affidavit, or other evidence, which places the application in condition for allowance; (2) a Notice of Appeal (with appeal fee) in compliance with 37 CFR 41.31; or (3) a Request for Continued Examination (RCE) in compliance with 37 CFR 1.114. The reply must be filed within one of the following time periods:

- a)  The period for reply expires \_\_\_\_\_ months from the mailing date of the final rejection.
- b)  The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection.

Examiner Note: If box 1 is checked, check either box (a) or (b). ONLY CHECK BOX (b) WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f).

Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### NOTICE OF APPEAL

2.  The Notice of Appeal was filed on \_\_\_\_\_. A brief in compliance with 37 CFR 41.37 must be filed within two months of the date of filing the Notice of Appeal (37 CFR 41.37(a)), or any extension thereof (37 CFR 41.37(e)), to avoid dismissal of the appeal. Since a Notice of Appeal has been filed, any reply must be filed within the time period set forth in 37 CFR 41.37(a).

#### AMENDMENTS

3.  The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will not be entered because

- (a)  They raise new issues that would require further consideration and/or search (see NOTE below);
- (b)  They raise the issue of new matter (see NOTE below);
- (c)  They are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or
- (d)  They present additional claims without canceling a corresponding number of finally rejected claims.

NOTE: \_\_\_\_\_. (See 37 CFR 1.116 and 41.33(a)).

4.  The amendments are not in compliance with 37 CFR 1.121. See attached Notice of Non-Compliant Amendment (PTOL-324).

5.  Applicant's reply has overcome the following rejection(s): \_\_\_\_\_.

6.  Newly proposed or amended claim(s) \_\_\_\_\_ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s).

7.  For purposes of appeal, the proposed amendment(s): a)  will not be entered, or b)  will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended.

The status of the claim(s) is (or will be) as follows:

Claim(s) allowed: \_\_\_\_\_.

Claim(s) objected to: \_\_\_\_\_.

Claim(s) rejected: 1-14.

Claim(s) withdrawn from consideration: \_\_\_\_\_.

#### AFFIDAVIT OR OTHER EVIDENCE

8.  The affidavit or other evidence filed after a final action, but before or on the date of filing a Notice of Appeal will not be entered because applicant failed to provide a showing of good and sufficient reasons why the affidavit or other evidence is necessary and was not earlier presented. See 37 CFR 1.116(e).

9.  The affidavit or other evidence filed after the date of filing a Notice of Appeal, but prior to the date of filing a brief, will not be entered because the affidavit or other evidence failed to overcome all rejections under appeal and/or appellant fails to provide a showing a good and sufficient reasons why it is necessary and was not earlier presented. See 37 CFR 41.33(d)(1).

10.  The affidavit or other evidence is entered. An explanation of the status of the claims after entry is below or attached.

#### REQUEST FOR RECONSIDERATION/OTHER

11.  The request for reconsideration has been considered but does NOT place the application in condition for allowance because:  
See Continuation Sheet.

12.  Note the attached Information Disclosure Statement(s). (PTO/SB/08) Paper No(s). \_\_\_\_\_

13.  Other: \_\_\_\_\_.

/Fereydoun G Sajjadi/  
Supervisory Patent Examiner, Art Unit 1617

Continuation of 11. does NOT place the application in condition for allowance because: The Examiner maintains the rejection of claims 1-14 under 103(a) over Nara et al. (US, 245, 351) and Rupprecht et al. (DE 10146251) for reasons of record. Applicant's arguments have been fully considered but are not found persuasive. First, Applicant argues that Stover case law that the facts do not resemble the instant invention because it would be nonsequencial to place the active ingredient in a film which coats Nara's core as this film is destroyed in providing the enteric effect. The Examiner disagrees with this argument because both Nara and Rupprecht are analogous and relate to method of making drug delivery devices and only differ in the why the active ingredients are dispersed within the process. Since, Rupprecht et al. teaches that the simultaneously spraying step provide uniform distributions of the components there is motivation to utilize the step in formulating drug films where the desired route of delivery is a sheet. Further, Applicant's argue that Nara and Rupprecht references did not appear to be considered as a whole. First, applicant's argue hydrophilic polymers are crosslinked by polyacrylic acid in situ which is not met by Nara. The Examiner is not persuaded by this argument because Nara teaches in Example 7 hydrophilic polymer, hydroxypropylcellulose is spray coated with a crosslinked polyacrylic polymer which would inherently crosslink in situ. Further, Applicant argues there is no mention of simultaneous spraying. The Examiner is not persuaded by this argument because because it is the combination of Nara and Rupprecht that is utilized to overcome the teachings of the prior art, not Nara alone and Applicant is seeking to perform a piecemeal analysis where the claims have been rejected based on a combination of references. Rupprecht et al teach formulating drugs in the form of a film where the solution are sprayed simultaneously was known at the time of invention and one would have been motivated to utilize the spraying device to formulation the present invention to form uniform distribution of the film-formed components.